Erratum: Structural investigation of B-raf paradox breaker and inducer inhibitors (Journal of Medicinal Chemistry (2015) 58 (1818-1831) DOI: 10.1021/jm501667n);Structural investigation of B-Raf paradox breaker and inducer inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 4, 2015, Pages 1818-1831

  Arora, Rohit ^a   Di Michele, Michela ^b,c   Stes, Elisabeth ^b,c   Vandermarliere, Elien ^b,c   Martens, Lennart ^b,c   Gevaert, Kris ^b,c   Van Heerde, Erika ^d   Linders, Joannes T M ^d   Brehmer, Dirk ^d   Jacoby, Edgar ^d   Bonnet, Pascal ^a  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; CELL PROLIFERATION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; HUMAN CELL; MISSENSE MUTATION; MOLECULAR DYNAMICS; PROTEIN DOMAIN; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923870007     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00941     Document Type: Erratum

References (42)

1. Robinson, M. J.; Cobb, M. H. Mitogen-Activated Protein Kinase Pathways Curr. Opin. Cell Biol. 1997, 9, 180-186
2. Kolch, W. Meaningful Relationships: The Regulation of the Ras/Raf/MEK/ERK Pathway by Protein Interactions Biochem. J. 2000, 351 (Pt 2) 289-305
3. Morrison, D. K.; Cutler, R. E. The Complexity of Raf-1 Regulation Curr. Opin. Cell Biol. 1997, 9, 174-179
4. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W. C.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF Gene in Human Cancer Nature 2002, 417, 949-954
5. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P. N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E. A.; Wong, B.; Tsang, G.; West, B. L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K. Y. J.; Artis, D. R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; DAndrea, K.; Koehler, A.; Stumm, M.; Lin, P. S.; Lee, R. J.; Grippo, J.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; Chapman, P. B.; Flaherty, K. T.; Xu, X.; Nathanson, K. L.; Nolop, K. Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-Mutant Melanoma Nature 2010, 467, 596-599
6. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S. M.; Fong, D.; Zhu, Y.-L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S.-H.; Schlessinger, J.; Zhang, K. Y. J.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 3041-3046
7. Wan, P. T. C.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Project, C. G.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF Cell 2004, 116, 855-867
8. Gibney, G. T.; Zager, J. S. Clinical Development of Dabrafenib in BRAF Mutant Melanoma and Other Malignancies Expert Opin. Drug Metab. Toxicol. 2013, 9, 893-899
9. Wang, X.; Kim, J. Conformation-Specific Effects of Raf Kinase Inhibitors J. Med. Chem. 2012, 55, 7332-7341
10. Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B. J.; Anderson, D. J.; Alvarado, R.; Ludlam, M. J. C.; Stokoe, D.; Gloor, S. L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoeflich, K. P.; Jaiswal, B. S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L. S.; Malek, S. RAF Inhibitors Prime Wild-Type RAF to Activate the MAPK Pathway and Enhance Growth Nature 2010, 464, 431-435
11. Heidorn, S. J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J. S.; Springer, C. J.; Pritchard, C.; Marais, R. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF Cell 2010, 140, 209-221
12. Poulikakos, P. I.; Zhang, C.; Bollag, G.; Shokat, K. M.; Rosen, N. RAF Inhibitors Transactivate RAF Dimers and ERK Signalling in Cells with Wild-Type BRAF Nature 2010, 464, 427-430
13. Su, F.; Viros, A.; Milagre, C.; Trunzer, K.; Bollag, G.; Spleiss, O.; Reis-Filho, J. S.; Kong, X.; Koya, R. C.; Flaherty, K. T.; Chapman, P. B.; Kim, M. J.; Hayward, R.; Martin, M.; Yang, H.; Wang, Q.; Hilton, H.; Hang, J. S.; Noe, J.; Lambros, M.; Geyer, F.; Dhomen, N.; Niculescu-Duvaz, I.; Zambon, A.; Niculescu-Duvaz, D.; Preece, N.; Robert, L.; Otte, N. J.; Mok, S.; Kee, D.; Ma, Y.; Zhang, C.; Habets, G.; Burton, E. A.; Wong, B.; Nguyen, H.; Kockx, M.; Andries, L.; Lestini, B.; Nolop, K. B.; Lee, R. J.; Joe, A. K.; Troy, J. L.; Gonzalez, R.; Hutson, T. E.; Puzanov, I.; Chmielowski, B.; Springer, C. J.; McArthur, G. A.; Sosman, J. A.; Lo, R. S.; Ribas, A.; Marais, R. RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors N. Engl. J. Med. 2012, 366, 207-215
14. Flaherty, K. T.; Infante, J. R.; Daud, A.; Gonzalez, R.; Kefford, R. F.; Sosman, J.; Hamid, O.; Schuchter, L.; Cebon, J.; Ibrahim, N.; Kudchadkar, R.; Burris, H. A.; Falchook, G.; Algazi, A.; Lewis, K.; Long, G. V.; Puzanov, I.; Lebowitz, P.; Singh, A.; Little, S.; Sun, P.; Allred, A.; Ouellet, D.; Kim, K. B.; Patel, K.; Weber, J. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations N. Engl. J. Med. 2012, 367, 1694-1703
15. Johnson, D. B.; Flaherty, K. T.; Weber, J. S.; Infante, J. R.; Kim, K. B.; Kefford, R. F.; Hamid, O.; Schuchter, L.; Cebon, J.; Sharfman, W. H.; McWilliams, R. R.; Sznol, M.; Lawrence, D. P.; Gibney, G. T.; Burris, H. A.; Falchook, G. S.; Algazi, A.; Lewis, K.; Long, G. V.; Patel, K.; Ibrahim, N.; Sun, P.; Little, S.; Cunningham, E.; Sosman, J. A.; Daud, A.; Gonzalez, R. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor J. Clin. Oncol. 2014, 10.1200/JCO.2014.57.3535
16. Ibrahim, P. N.; Zhang, C.; Spevak, W.; Zhang, J.; Wu, G.; Lin, J.; Cho, H.; Nespi, M.; Shi, S.; Ewing, T.; Zhang, Y. Preparation of pyrrolo[2,3-b]pyridine compounds as kinase modulators for disease treatment. International patent WO 2012109075, 2012.
17. Le, K.; Blomain, E. S.; Rodeck, U.; Aplin, A. E. Selective RAF Inhibitor Impairs ERK1/2 Phosphorylation and Growth in Mutant NRAS, Vemurafenib-Resistant Melanoma Cells Pigm. Cell Melanoma Res. 2013, 26, 509-517
18. Okaniwa, M.; Hirose, M.; Arita, T.; Yabuki, M.; Nakamura, A.; Takagi, T.; Kawamoto, T.; Uchiyama, N.; Sumita, A.; Tsutsumi, S.; Tottori, T.; Inui, Y.; Sang, B.-C.; Yano, J.; Aertgeerts, K.; Yoshida, S.; Ishikawa, T. Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives J. Med. Chem. 2013, 56, 6478-6494
19. Nakamura, A.; Arita, T.; Tsuchiya, S.; Donelan, J.; Chouitar, J.; Carideo, E.; Galvin, K.; Okaniwa, M.; Ishikawa, T.; Yoshida, S. Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma Cancer Res. 2013, 73, 7043-7055
20. Wang, L.; Perera, B. G. K.; Hari, S. B.; Bhhatarai, B.; Backes, B. J.; Seeliger, M. A.; Schürer, S. C.; Oakes, S. A.; Papa, F. R.; Maly, D. J. Divergent Allosteric Control of the IRE1α Endoribonuclease Using Kinase Inhibitors Nat. Chem. Biol. 2012, 8, 982-989
21. Koppikar, P.; Bhagwat, N.; Kilpivaara, O.; Manshouri, T.; Adli, M.; Hricik, T.; Liu, F.; Saunders, L. M.; Mullally, A.; Abdel-Wahab, O.; Leung, L.; Weinstein, A.; Marubayashi, S.; Goel, A.; Gönen, M.; Estrov, Z.; Ebert, B. L.; Chiosis, G.; Nimer, S. D.; Bernstein, B. E.; Verstovsek, S.; Levine, R. L. Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy Nature 2012, 489, 155-159
22. Di Michele, M.; Stes, E.; Vandermarliere, E.; Arora, R.; Astorga-Wells, J.; Vandenbussche, J.; van Heerde, E.; Zubarev, R.; Bonnet, P.; Linders, J.; Jacoby, E.; Brehmer, D.; Martens, L.; Gevaert, K. Unpublished results.
23. Molecular Operating Environment (MOE), 2013.08; ChemicalComputing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal,QC, Canada, H3A 2R7, (2013.
24. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy J. Med. Chem. 2004) 47, 1739-1749
25. Case, D.; Darden, T.; Cheatham, T.; Simmerling, C.; Wang, J.; Duke, R.; Luo, R.; Walker, R.; Zhang, W.; Merz, K.; Roberts, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Swails, J.; Goetz, A.; Kolossváry, I.; Wong, K.; Paesani, F.; Vanicek, J.; Wolf, R.; Liu, J.; Wu, X.; Brozell, S.; Steinbrecher, T.; Gohlke, H.; Cai, Q.; Ye, X.; Wang, J.; Hsieh, M.; Cui, G.; Roe, D.; Mathews, D.; Seetin, M.; Salomon-Ferrer, R.; Sagui, C.; Babin, V.; Luchko, T.; Gusarov, S.; Kovalenko, A.; Kollman, P. AMBER 12, 2012.
26. Wang, J.; Wang, W.; Kollmann, P.; Case, D. Antechamber, An Accessory Software Package For Molecular Mechanical Calculation J. Comput. Chem. 2005, 25, 1157-1174
27. Walker, R. C.; Crowley, M. F.; Case, D. A. The Implementation of a Fast and Accurate QM/MM Potential Method in Amber J. Comput. Chem. 2008, 29, 1019-1031
28. Roe, D. R.; Cheatham, T. E. PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data J. Chem. Theory Comput. 2013, 9, 3084-3095
29. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual Molecular Dynamics J. Mol. Graph. 1996, 14, 33-38
30. Grant, B. J.; Rodrigues, A. P. C.; ElSawy, K. M.; McCammon, J. A.; Caves, L. S. D. Bio3d: An R Package for the Comparative Analysis of Protein Structures Bioinformatics 2006, 22, 2695-2696
31. Delano, W. The PyMOL Molecular Graphics System, 2002.
32. Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays J. Immunol. Methods 1983, 65, 55-63
33. Mérour, J. Y.; Buron, F.; Plé, K.; Bonnet, P.; Routier, S. The Azaindole Framework in the Design of Kinase Inhibitors Molecules 2014, 19, 19935-19979
34. Azam, M.; Seeliger, M. A.; Gray, N. S.; Kuriyan, J.; Daley, G. Q. Activation of Tyrosine Kinases by Mutation of the Gatekeeper Threonine Nat. Struct. Mol. Biol. 2008, 15, 1109-1118
35. Lavoie, H.; Li, J. J.; Thevakumaran, N.; Therrien, M.; Sicheri, F. Dimerization-Induced Allostery in Protein Kinase Regulation Trends Biochem. Sci. 2014, 39, 475-486
36. Lavoie, H.; Thevakumaran, N.; Gavory, G.; Li, J. J.; Padeganeh, A.; Guiral, S.; Duchaine, J.; Mao, D. Y. L.; Bouvier, M.; Sicheri, F.; Therrien, M. Inhibitors That Stabilize a Closed RAF Kinase Domain Conformation Induce Dimerization Nat. Chem. Biol. 2013, 9, 428-436
37. Taipale, M.; Krykbaeva, I.; Koeva, M.; Kayatekin, C.; Westover, K. D.; Karras, G. I.; Lindquist, S. Quantitative Analysis of HSP90-Client Interactions Reveals Principles of Substrate Recognition Cell 2012, 150, 987-1001
38. Jambrina, P. G.; Bohuszewicz, O.; Buchete, N.-V.; Kolch, W.; Rosta, E. Molecular Mechanisms of Asymmetric RAF Dimer Activation Biochem. Soc. Trans. 2014, 42, 784-790
39. Bamford, S.; Dawson, E.; Forbes, S.; Clements, J.; Pettett, R.; Dogan, A.; Flanagan, A.; Teague, J.; Futreal, P. A.; Stratton, M. R.; Wooster, R. The COSMIC (Catalogue of Somatic Mutations in Cancer) Database and Website Br. J. Cancer 2004, 91, 355-358
40. Deichmann, M.; Thome, M.; Benner, A.; Kirschner, M.; Hassanzadeh, J.; Kurzen, H. Preponderance of the Oncogenic V599E and V599K Mutations in B-Raf Kinase Domain Is Enhanced in Melanoma Cutaneous/subcutaneous Metastases BMC Cancer 2005, 5 58
41. Deichmann, M.; Krahl, D.; Thome, M.; Wüst, K.; Hassanzadeh, J.; Helmke, B. The Oncogenic B-Raf V599E Mutation Occurs More Frequently in Melanomas at Sun-Protected Body Sites Int. J. Oncol. 2006, 29, 139-145
42. Pignochino, Y.; Grignani, G.; Cavalloni, G.; Motta, M.; Tapparo, M.; Bruno, S.; Bottos, A.; Gammaitoni, L.; Migliardi, G.; Camussi, G.; Alberghini, M.; Torchio, B.; Ferrari, S.; Bussolino, F.; Fagioli, F.; Picci, P.; Aglietta, M. Sorafenib Blocks Tumour Growth, Angiogenesis and Metastatic Potential in Preclinical Models of Osteosarcoma through a Mechanism Potentially Involving the Inhibition of ERK1/2, MCL-1 and Ezrin Pathways Mol. Cancer 2009, 8 118